Emergent Biosystems (NYSE:EBS) inks an agreement with GlaxoSmithKline (NYSE:GSK) to acquire raxibacumab, a fully human monoclonal antibody for the treatment and prevention of inhaled anthrax, for $76M in upfront cash and up to $20M in milestones.
{iframe}https://seekingalpha.com/news/3279657-emergent-bio-buys-anthrax-biologic-raxibacumab-glaxo-96m?utoken=77cea408193abfd0b8876d8484dacaab#email_link{/iframe}
